Health Care

Endocyte, Inc. (NASDAQ: ECYT) on Thursday announced its $2.1-billion cash sale to Novartis AG (NYSE: NVS). The deal values Endocyte at $24 per share, representing a 54-percent premium from the firm’s $15.56 Wednesday closing price. Why It’s Important Endocyte's radioligand...

Weed's role as a natural painkiller without the addictive properties of opioids is well-known, as is cannabidiol's helpfulness in combating seizures and anxiety.  Studies and evidence support CBD's effectiveness in improving the behavior of children on the autism spectrum...

Medical device company SI-Bone, Inc. is set to begin trading on the Nasdaq Global Market under the ticker symbol “SIBN.” The Company SI-Bone has pioneered a minimally invasive surgical implant system to fuse the sacroiliac joint, according to its S-1 filing. The iFuse...

Shares of clinical-stage pharmaceutical company vTv Therapeutics Inc. (NASDAQ: VTVT) surged 50 percent Wednesday morning. What Happened The company is engaged in the research and development of treatments for Alzheimer’s disease and diabetes. This week, it announced the delivery of an...

A closer look at Akorn, Inc. (NASDAQ: AKRX)'s generics business led Piper Jaffray to turn bullish on the drug manufacturer's stock.  The Analyst Analyst David Amsellem upgraded Akorn from Neutral to Overweight and raised the price target from $5 to $9. The Thesis Akorn's EBITDA has...

When anger over EpiPen pricing erupted in 2016, generic drugmaker Mylan NV (NASDAQ: MYL) was villainized.  The price of the autoinjector used for severe allergic reactions was hiked by about 500 percent between 2007 and 2016.  Both Democrats and Republicans came out strongly against...

As a way to leverage the newly budding cannabis space, Canopy Growth Corp. (NYSE: CGC) has taken several proactive steps in diversification. What Happened Canopy Growth on Monday announced it has entered into an agreement to acquire the assets of ebbu, Inc., a leader in hemp research. The...

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud. PhaseBio Pharmaceuticals Inc (PHAS) will issue 5 million shares between $12 and $14 Thursday on the Nasdaq. Based in Pennsylvania, the clinical-stage biopharmaceutical develops and commercializes therapies for orphan...

Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European Society For Medical Oncology, or ESMO, 2018 Congress – Oct. 19-23, in Munich, Germany 11th Annual Conference on Stem Cell and Regenerative Medicine – Oct. 15-16...

Fitness tracker Fitbit Inc (NYSE: FIT)'s announcement it will enter the health care and medical technology space is a bullish catalyst for the stock. The Analyst Wedbush analysts led by Michael Pachter upgraded Fitbit from Neutral to Outperform with an unchanged $6.50 price target. The...

Robotic surgery device manufacturer Intuitive Surgical, Inc. (NASDAQ: ISRG) reports third-quarter earnings Oct. 18. Piper Jaffray outlined the results of a physician survey in an upgrade note issued ahead of the print.  The Analyst Analyst JP McKim upgraded Intuitive Surgical from Neutral...

A day after Trevena Inc (NASDAQ: TRVN) shares suffered a setback in reaction to a FDA committe's briefing document, another stock is trading higher following the release of a briefing document pertaining to its adcom review. What Happened The briefing document released by FDA's...

Akorn, Inc. (NASDAQ: AKRX) shares — which tumbled roughly 60 percent to $5.36 Oct. 1 on a ruling that Fresenius SE is free to exit its M&A agreement with Akorn —  had a reprieve early Wednesday. What Happened The generic pharma company announced FDA approval for...

Trevena Inc (NASDAQ: TRVN) has a key catalyst Oct. 11, when the FDA's Anesthetic and Analgesic Drug Products Advisory Committee is scheduled to announce its verdict on the safety, efficacy and benefit considerations for the company's pain medication candidate Oliceridine. Ahead of the D-...

By J.J. McCoy, Senior Managing Editor, for New Frontier Data Recent news that the U.S. Drug Enforcement Agency (DEA) is rescheduling cannabidiol (CBD) for use in FDA-approved medicine was warmly welcomed by the cannabis industry, but it felt confusingly tepid on delivery. Overall, the...